Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP & Chief Financial Officer | September 30, 2026 | October 03, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Executive VP & CFO | October 11, 2024 | October 15, 2024 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Executive Vice President & COO | July 01, 2022 | July 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,762 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 10 · Balance 27,762 F1: The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to the Company's Employee Stock Purchase Plan at the fair market value of the Company's common stock on the purchase date. The Reporting Person elected to participate in the Plan during an open trading window prior to the commencement of the quarterly purchase period.
DENTSPLY SIRONA Inc.
Report date October 11, 2024 · Filed October 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,767.654 |
Reported balance
After 2024-10-11 transaction · row 1
1 source rowRow 1 · 2024-10-11 · Grant · Acquired 375.279 · Balance 89,767.654 F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. |
| Phantom Stock (Supplemental Executive Retirement Plan) SERPSEC Table II · derivative / convertible security | Direct | 1,892.0687 |
Reported balance
After 2024-10-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-11 · Grant · Acquired 12.2776 · Balance 1,892.0687 F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting persons termination of employment. F3: Comprised of phantom stock acquired as a result of accrued dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
F2: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock upon the reporting persons termination of employment.
F3: Comprised of phantom stock acquired as a result of accrued dividends.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date July 01, 2022 · Filed July 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,622 |
Reported balance
After 2022-07-01 transaction · row 1
1 source rowRow 1 · 2022-07-01 · Tax withholding · Disposed 6,666 · Balance 34,622 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Premier, Inc.
Report date November 25, 2025 · Filed November 26, 2025
Section 16 reporting ended · disclosed 2025-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-11-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-11-25 · Disposition to issuer · Disposed 161,464 · Balance 32,018 F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement. F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents). Row 2 · 2025-11-25 · Disposition to issuer · Disposed 32,018 · Balance 0 F3: Reflects the cancellation at the Effective Time of RSUs granted to the reporting person on or after August 16, 2025. Pursuant to the Merger Agreement, these RSUs were cancelled in connection with the Merger for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement.
F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents).
F3: Reflects the cancellation at the Effective Time of RSUs granted to the reporting person on or after August 16, 2025. Pursuant to the Merger Agreement, these RSUs were cancelled in connection with the Merger for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2021 Filed Apr 19, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 25,658 | $71.50 | $1,834,547.00 |
DisclosureSEC source: 0001209191-21-027283 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,056 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 25,658 | $19.41 | $498,021.78 |
DisclosureSEC source: 0001209191-21-027283 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,002 | $70.50 | $282,141.00 |
DisclosureSEC source: 0001209191-21-026821 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,056 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 20:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $19.41 | $0.00 |
DisclosureSEC source: 0001209191-21-026363 · doc4.xml · derivative · entry 3 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,658 Underlying: Common Stock · 12,500 shares Expires 2022-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · derivative.exercise_date: 25% of the stock options vested every first, second, third and fourth anniversaries of the grant date of 5/2/2014. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 20:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 12,500 | $70.00 | $875,000.00 |
DisclosureSEC source: 0001209191-21-026363 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,058 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 20:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 12,500 | $19.41 | $242,625.00 |
DisclosureSEC source: 0001209191-21-026363 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $19.41 Strike: $19.41 | $242,625.00 |
DisclosureSEC source: 0001209191-21-023607 · doc4.xml · derivative · entry 4 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,158 Underlying: Common Stock · 12,500 shares Expires 2022-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to Rule 10b5-1 trading plans previously adopted by the reporting person. F2 · derivative.exercise_date: 25% of the stock options vested every first, second, third and fourth anniversaries of the grant date of 5/2/2014. F3 · balance_after: This option was previously reported as covering 24,264 shares at an exercise price of $44.87 per share, but was adjusted pursuant to the antidilution provisions of the award in connection with the spin-off of SeaSpine Holdings Corporation on July 1, 2015. F4 · balance_after: In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 12,500 | $68.50 | $856,250.00 |
DisclosureSEC source: 0001209191-21-023607 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,058 F1 · kind: The transactions reported in this Form 4 were affected pursuant to Rule 10b5-1 trading plans previously adopted by the reporting person. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 12,500 | $19.41 | $242,625.00 |
DisclosureSEC source: 0001209191-21-023607 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to Rule 10b5-1 trading plans previously adopted by the reporting person. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,000 | $68.50 | $205,500.00 |
DisclosureSEC source: 0001209191-21-023607 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,058 F1 · kind: The transactions reported in this Form 4 were affected pursuant to Rule 10b5-1 trading plans previously adopted by the reporting person. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 515 | $68.10 | $35,071.50 |
DisclosureSEC source: 0001209191-21-020757 · doc4.xml · nonDerivative · entry 4 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,058 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 523 | $68.10 | $35,616.30 |
DisclosureSEC source: 0001209191-21-020757 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,573 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 990 | $68.10 | $67,419.00 |
DisclosureSEC source: 0001209191-21-020757 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,096 Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,518 | $0.00 Strike: $68.10 | $0.00 |
DisclosureSEC source: 0001209191-21-020757 · doc4.xml · derivative · entry 5 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,518 Underlying: Common Stock · 20,518 shares Expires 2029-03-12 F2 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/12/2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020757 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,086 F1 · balance_after: Includes 385 shares acquired under the Integra Employee Stock Purchase Plan since the date of the reporting person's most recent filing on Form 4. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 21:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 2,600 | $56.03 | $145,666.30 |
DisclosureSEC source: 0001209191-20-058705 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,894 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $56.00 to $56.14. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,400 | $56.04 | $246,596.68 |
DisclosureSEC source: 0001209191-20-057912 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $56.00 to $56.135. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 93 | $55.04 | $5,118.72 |
DisclosureSEC source: 0001209191-20-057912 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,894 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:08 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,907 | $54.34 | $266,668.46 |
DisclosureSEC source: 0001209191-20-057912 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,987 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $54.005 to $54.95. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 5,000 | $52.27 | $261,342.50 |
DisclosureSEC source: 0001209191-20-046586 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · Executive Vice President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,894 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $52.00 to $53.03. F1 · acquired: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 43,746 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · derivative · entry 8 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,746 Underlying: Common Stock · 43,746 shares Expires 2028-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 2,300 | $43.39 | $99,797.00 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 7 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,894 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,568 | $43.39 | $68,035.52 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 6 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,194 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,211 | $43.39 | $52,545.29 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 5 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,762 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 8,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 4 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,973 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 719 | $43.39 | $31,197.41 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,215 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 751 | $43.39 | $32,585.89 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,934 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 883 | $43.39 | $38,313.37 |
DisclosureSEC source: 0001209191-20-019552 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,685 Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:36 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010167 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,568 F4 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the first anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:36 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010167 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,871 F3 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:36 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010167 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,336 F1 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019, at least 9% and up to a maximum of 33% cumulative increase in annual revenue over the 2016 fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 34% of the shares will vest on March 13, 2020 at 150% of target, the third anniversary of the grant date. F2 · balance_after: Includes 428 shares acquired under the Integra Employee Stock Purchase Plan since the date of the reporting person's most recent filing on Form 4. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,500 | $57.50 | $201,250.00 |
DisclosureSEC source: 0001209191-19-043328 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,194 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 18:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 13,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040848 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,694 Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,650 | $55.00 | $200,750.00 |
DisclosureSEC source: 0001209191-19-040218 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,160 F1 · kind: The transaction reported in this Form 4 was affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 721 | $56.14 | $40,476.94 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 7 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,810 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 2,700 | $56.14 | $151,578.00 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 6 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,531 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,678 | $0.00 Strike: $55.91 | $0.00 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · derivative · entry 8 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,678 Underlying: Common Stock · 20,678 shares Expires 2027-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, and third anniversaries of the grant date of 3/13/2019. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 718 | $55.91 | $40,143.38 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 5 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,231 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 856 | $55.91 | $47,858.96 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 4 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,949 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,805 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,191 | $55.91 | $66,588.81 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,184 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 2,232 | $55.91 | $124,791.12 |
DisclosureSEC source: 0001209191-19-019754 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:49 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011119 · doc4.xml · nonDerivative · entry 3 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,607 F4 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2019 at 89.5% of target, the first anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:49 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011119 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,346 F3 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2019 at 150% of target, the second anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:49 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 5,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011119 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,830 F1 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 34% of the shares will vest on March 14, 2019 at 150% of target, the third anniversary of the grant date. F2 · balance_after: Includes 554 shares acquired under the Integra Employee Stock Purchase Plan since the date of the reporting person's most recent filing on Form 4. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:35 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 8,916 | $63.00 | $561,727.62 |
DisclosureSEC source: 0001209191-18-046236 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,795 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $63 to $63.011. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,777 | $62.00 | $110,174.00 |
DisclosureSEC source: 0001209191-18-028073 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,711 Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:06 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 4,441 | $62.00 | $275,342.00 |
DisclosureSEC source: 0001209191-18-028073 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,488 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 551 | $54.15 | $29,836.65 |
DisclosureSEC source: 0001209191-18-021794 · doc4.xml · nonDerivative · entry 2 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,929 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 937 | $54.15 | $50,738.55 |
DisclosureSEC source: 0001209191-18-021794 · doc4.xml · nonDerivative · entry 1 Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,480 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.